Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026

Loading news article.

Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026 | WAPE

Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted For Late-Breaking Oral Presentation At EHA 2026

Article summary

Related companies

Comments —